ASTRAZEN:NSIprice moved over-1.86%to 7,200.70Dec 30 2024 About the company AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare seg...
A company profile report for AstraZeneca Pharma India Limited (AZPIL) from publisher Life Science Analytics Inc. is presented, with topics including management profile, company announcements, deals, alliances and product updates.EBSCO_bspAstrazeneca Pharma India Limited Medtrack Company Profile...
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
阿斯利康 (AstraZeneca) 对 Fusion Pharmaceuticals 的收购是一波并购活动中的最新一起,其中包括礼来 (Eli Lilly) 和百时美施贵宝 (Bristol Myers Squibb) 最近的交易。 主要的 Fusion 项目正处于治疗晚期前列腺癌的中期临床开发阶段。 作者:弗兰克·文卢安 阿斯利康 (AstraZeneca) 紧随一些大型制药公司同行的脚步,斥资 ...
以计算AstraZeneca Pharma India的保险结算为例,见下文:计算示例 行业基准分析 板块 上图描述了发展中经济区的板块医疗保健公司保险结算的分布情况。我们分析了超过40家公司,其中45家的数据为有效数据。这些板块公司的平均保险结算为22.85 M,标准差为39.589 M。 AstraZeneca Pharma India的保险结算排名为第-名,处于...
Finally, AstraZeneca will share preclinical data on AZD8205, a novel ADC targeting B7-H4, a protein overexpressed in a range of solid tumors. AZD8205 is the first ADC to incorporate the company’s linker technology. “We are serious about leading a revolution in oncology, wh...
AstraZeneca Pharma India的现价与52周高点的百分比值是79.4%. 查看AstraZeneca Pharma India的现价与52周高点的百分比值趋势、图表等
AstraZeneca Pharma India Limited has received import and market permission in Form CT-20 from the Drugs Controller General of India for selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of paediatric patients 3 years of age and older with ...
阿斯利康(AstraZeneca)今日宣布,已达成最终协议,拟斥资10.5亿美元收购致力于开发针对罕见内分泌疾病的创新疗法的生物技术公司Amolyt Pharma。这项拟议的收购将使阿斯利康获得名为eneboparatide(AZP-3601)的研发项目。Eneboparatide是一种处于3期临床研究的治疗性多肽,具有创新作用机制,旨在满足甲状旁腺功能减退症(hypoparath...
At AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for...